Piramal gets USDFA nod for anti-diabetic molecule

Piramal Enterprises today said it has received approval from the USFDA for its investigational new drug, P11187, that aims to target diabetes.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news